Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which i…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Arch Biopartners to Expand Ongoing Phase 2 LSAT Peptide Trial to The US Arch Biopartners (ARCH.V) will expand its Phase II trial of LSALT peptide into the US, with five ins | MMT Newswires | |
Arch Biopartners Says Toronto's St Mike's Hospital Begins Patient Dosing In Phase II LSALT Peptide Trial Arch Biopartners (ARCH.V) said Friday that St. Michael's Hospital (SMH) in Toronto, has begun patien | MMT Newswires | |
 Arch Biopartners appoints Patrick Vink as chairman of the board Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15. Vink has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. Vink’s appointment follows the retirement of Claude Allary from the Board of Directors.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investi | ||
Arch Biopartners Acquires Platform to Develop New Drugs Targeting Chronic Kidney Disease Arch Biopartners (ARCH.V) on Wednesday said it has acquired a pre-clinical platform developing new d | MMT Newswires | |